1. Articles in category: Side-Effects

    1-24 of 52 1 2 3 »
    1. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

      A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

      Int J Cancer. 2017 Jan 15;140(2):480-484

      Authors: Kushner BH, Cheung NV, Modak S, Becher OJ, Basu EM, Roberts SS, Kramer K, Dunkel IJ

      Read Full Article
      Mentions: MYCN
    2. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)

      The c-Met receptor tyrosine kinase is dysregulated in many pediatric cancers. Tivantinib is an oral small molecule that inhibits the c-Met receptor tyrosine kinase. A phase 1 and pharmacokinetic (PK) trial evaluating tivantinib was conducted in children with relapsed/refractory solid tumors.

      Read Full Article
      Mentions: COG Refractory
    3. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.

      Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.

      Pediatr Blood Cancer. 2017 Apr 24;:

      Authors: Mody R, Zhao L, Yanik GA, Opipari V

      Abstract PURPOSE: Prognosis for relapsed/refractory high-risk neuroblastoma (HR-NBL) remains poor. Bortezomib, a proteasome inhibitor, has shown preclinical activity against NBL as a single agent and in combination with cytotoxic chemotherapy including irinotecan.

      Read Full Article
    4. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma

      Prognosis for relapsed/refractory high-risk neuroblastoma (HR-NBL) remains poor. Bortezomib, a proteasome inhibitor, has shown preclinical activity against NBL as a single agent and in combination with cytotoxic chemotherapy including irinotecan.

      Eighteen HR-NBL patients with primary refractory (n = 8) or relapsed (n = 10) disease were enrolled in a Phase I study using modified Time To Event Continual Reassessment Method.

      Read Full Article
    5. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

      A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

      Clin Cancer Res. 2017 Apr 21;:

      Authors: Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, Marabelle A, Pearson ADJ, Modak S, Cash T, Robinson GW, Motta M, Matano A, Bhansali SG, Dobson JR, Parasuraman S, Chi SN

      Read Full Article
    6. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

      Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

      Exp Biol Med (Maywood). 2017 Jan 01;:1535370217706952

      Authors: Cooper JP, Reynolds CP, Cho H, Kang MH

      Abstract Fenretinide (4-HPR) is a synthetic retinoid that has cytotoxic activity against cancer cells.

      Read Full Article
    7. ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      Scientists from The Institute of Cancer Research, London, have been awarded £1.5 million by the charity Children with Cancer UK to advance precision medicine in the UK and improve cancer treatment for children and young adults.

      Read Full Article
      Mentions: Treatment
    8. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Eur J Cancer. 2017 Mar 19;76:188-196

      Authors: Kraal KC, Bleeker GM, van Eck-Smit BL, van Eijkelenburg NK, Berthold F, van Noesel MM, Caron HN, Tytgat GA

      Read Full Article
      Mentions: GPOH MIBG
    9. Premature physeal closure following 13-cis-retinoic acid and prolonged fenretinide administration in neuroblastoma

      "Retinoid therapy has contributed to improved outcomes in neuroblastoma. Clinical trials of fenretinide report favorable toxicity and disease stabilization in patients with high risk (HR) neuroblastoma. Skeletal effects have been described with other retinoids, but not with fenretinide to date. Two patients with HR, metastatic, refractory neuroblastoma received protracted courses of oral fenretinide for more than 5 years’ duration. Both developed premature long bone physeal closure, causing limb length discrepancies; their neuroblastoma remains in remission. The radiographic and clinical findings reported suggest these skeletal abnormalities may be a consequence of treatment with 13-cis-retinoic acid (13cisRA) followed ...

      Read Full Article
    10. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.

      Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.

      Bone Marrow Transplant. 2016 May 9;

      Authors: Desai AV, Heneghan MB, Li Y, Bunin NJ, Grupp SA, Bagatell R, Seif AE

      Read Full Article
    11. Children's Hospital of Michigan DMC Research Team Leads Clinical Trial to Protect the Hearts of Children Who Receive Chemotherapy

      Published in the upcoming March 10, 2016 issue of the authoritative Journal of Clinical Oncology, this new study is likely to change the standard of cardiac care during treatment of many childhood cancer patients.

      Read Full Article
    12. Evaluation and Management of Hearing Loss in Survivors of Childhood and Adolescent Cancers: A Report From the Children's Oncology Group

      Hearing loss (HL) is common in childhood cancer survivors exposed to platinum chemotherapy and/or cranial radiation and can severely impact quality of life. Early detection and appropriate management can mitigate academic, speech, language, social, and psychological morbidity resulting from hearing deficits. This review is targeted as a resource for providers involved in aftercare of childhood cancers.

      Read Full Article
    13. Impaired Left Ventricular Reserve in Childhood Cancer Survivors Treated With Anthracycline Therapy

      Childhood cancer survivors show evidence of diffuse myocardial fibrosis that is related to exercise capacity. The mechanism of reduced exercise tolerance in anthracycline cardiotoxicity remains unclear. We explored the determinants of exercise intolerance by evaluating left ventricular (LV) distensibility and functional reserve.

      Read Full Article
    14. Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.

      "The mean administered activity was 11089±7222 MBq and the mean whole-body dose for a single administration was 1.79±0.57 Gy. Tumour-absorbed doses varied considerably (3.70±3.37 mGy/MBq). CTCAE grade 3/4 neutropenia was documented following 82% treatments and grade 3/4 thrombocytopenia following 71% treatments. Further acute toxicity was found in 49% of patients. All acute toxicities resolved with appropriate therapy. The overall response rate was 58% (complete or partial response), with a further 29% of patients having stable disease."

      Read Full Article
    15. Short-Interval Retreatment With Stereotactic Body Radiotherapy (SBRT) for Pediatric Neuroblastoma Resulting in Severe Myositis.

      "We report a severe and not previously reported toxicity after short-interval retreatment with stereotactic body radiotherapy (SBRT) in a pediatric patient with neuroblastoma. This patient experienced Grade III radiation myositis [inflammation and degeneration of muscle tissue] after treatment with conventional radiation therapy followed by high-dose SBRT for persistent disease a short interval after the initial radiotherapy course. While SBRT shows outstanding rates of local control in adult disease, data in pediatric cancers are extremely limited. In this report, we discuss the rationale of SBRT in this patient's multimodality neuroblastoma treatment, management of the toxicity, and future perspectives on the ...

      Read Full Article
      Mentions: Radiotherapy
    16. Short-Interval Retreatment With Stereotactic Body Radiotherapy (SBRT) for Pediatric Neuroblastoma Resulting in Severe Myositis

      We report a severe and not previously reported toxicity after short-interval retreatment with stereotactic body radiotherapy (SBRT) in a pediatric patient with neuroblastoma. This patient experienced Grade III radiation myositis after treatment with conventional radiation therapy followed by high-dose SBRT for persistent disease a short interval after the initial radiotherapy course.

      Read Full Article
    17. Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers.

      "Thirty-five patients, median age 4, in Boston (2007-2011) and 38 patients, median age 3, in Cairo (2009-2011). Renal toxicity; creatinine was significantly higher in CEM than Bu/Mel: 57% (median day+90) vs. 29% (median>day+100), p = 0.004. One CEM patient died from renal dialysis at day+19. Hepatic toxicity was significantly higher in CEM than Bu/Mel: 80% (median day+26) vs. 58% (median day+60), p = 0.04. In infectious complications with CEM 14%, bacteremia (n = 4) and fungemia (n = 1), 3 had culture-negative sepsis requiring vasopressors. With Bu/Mel 18%, bacteremia (n = 7), none required ...

      Read Full Article
    18. Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an in vitro study.

      Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an in vitro study.

      Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an in vitro study.

      PLoS One. 2014;9(8):e104888

      Authors: Kobashigawa LC, Xu YC, Padbury JF, Tseng YT, Yano N

      Abstract Doxorubicin (Dox) is one of the most widely used antitumor drugs, but its cumulative cardiotoxicity have been major concerns in cancer therapeutic practice for decades.

      Read Full Article
    19. Risk Factors and Clinical Features of Cytomegalovirus Disease in Children Receiving Anticancer Chemotherapy.

      Risk Factors and Clinical Features of Cytomegalovirus Disease in Children Receiving Anticancer Chemotherapy.

      J Pediatr Hematol Oncol. 2015 Oct 29;

      Authors: Han MS, Lee HJ, Lee H, Choe YJ, Lee JW, Kang HJ, Park KD, Shin HY, Jung HJ, Choi EH

      Abstract This study was conducted to identify risk factors for cytomegalovirus (CMV) infection and demonstrate the spectrum of CMV disease in children receiving anticancer chemotherapy without hematopoietic stem cell transplantation (HSCT).

      Read Full Article
    20. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131I-Metaiodobenzylguanidine (MIBG)

      131I-metaiodobenzylguanidine (131I-MIBG) is a targeted radiopharmaceutical for patients with neuroblastoma. Despite its tumor-specific uptake, the treatment with 131I-MIBG results in whole-body radiation exposure. Our aim was to correlate whole-body radiation dose (WBD) from 131I-MIBG with tumor response, toxicities, and other clinical factors.

      Read Full Article
      Mentions: MIBG
    21. Which Variables are Useful for Predicting Severe Infection in Children With Febrile Neutropenia?

      Which Variables are Useful for Predicting Severe Infection in Children With Febrile Neutropenia?

      J Pediatr Hematol Oncol. 2015 Oct 16;

      Authors: Delebarre M, Garnier N, Macher E, Thebaud E, Mazingue F, Leblond P, Duhamel A, Martinot A, Dubos F

      Abstract To distinguish children with chemotherapy-induced febrile neutropenia (FN) at low risk of severe infection, the variables that are significant risk factors must be identified.

      Read Full Article
      Mentions: Chemotherapy
    1-24 of 52 1 2 3 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) MYCN